GGrantIndex
← Search

Animal Model Shared Resource

$346,226P30FY2023CANIH

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications, trials & patents

Paper 39499645Paper 39392861Paper 39378878Paper 39332920Paper 39259591Paper 39207105Paper 39193906Paper 39127153Paper 39081315Paper 39028768Paper 39025270Paper 38902475Paper 38898085Paper 38896451Paper 38863869Paper 38778498Paper 38753503Paper 38717519Paper 38700353Paper 38699331Paper 38679747Paper 38657656Paper 38645169Paper 38643166Paper 38608634Paper 38597673Paper 38571760Paper 38565851Paper 38559037Paper 38477945Paper 38463959Paper 38458178Paper 38436133Paper 38405931Paper 38402617Paper 38400039Paper 38387080Paper 38352476Paper 38334805Trial NCT05016622Trial NCT04514484Trial NCT04401670Trial NCT03648983Trial NCT02774291Trial NCT02649569Trial NCT02578888Trial NCT02575872Trial NCT02527304Trial NCT02507076Trial NCT02382419Trial NCT02277561Trial NCT02112552Trial NCT02073968Trial NCT02038153Trial NCT02009436Trial NCT01958580Trial NCT01939210Trial NCT01899326Trial NCT01899261Trial NCT01897454Trial NCT01897441Trial NCT01857271Trial NCT01772420Trial NCT01697293Trial NCT01695941Trial NCT01605032Trial NCT01408160Trial NCT01367301Trial NCT01351909Trial NCT01319539Trial NCT01231906Trial NCT01145430Trial NCT01142401Trial NCT01061606Trial NCT01041027Trial NCT01001910Trial NCT00950365Trial NCT00470301Trial NCT00450944Trial NCT00437034Trial NCT00392353Trial NCT00324740Trial NCT00182767Trial NCT00179348Trial NCT00121251Trial NCT00096317Trial NCT00066638Trial NCT00057863Trial NCT00055692Trial NCT00030706Trial NCT00019474Trial NCT00004864Trial NCT00004863Trial NCT00003867Trial NCT00002461Patent 9671391Patent 7709613Patent 6821725Patent 6013468Patent 5876979

Abstract

Program Director/Principal Investigator (Last, First, Middle): Chu, Edward ANIMAL MODEL SHARED RESOURCE - PROJECT SUMMARY/ABSTRACT The objective of the Animal Model Shared Resource (AMSR) is to provide a comprehensive a service for the generation, housing, and analysis of mouse models of human cancer. The AMSR provides services for the modification of the mouse genome through CRISPR/Cas9 gene targeting technology as well as conventional gene targeting in embryonic stem (ES) cells. The AMSR generates conventional knockout mouse lines, knock- in mouse lines and mouse lines with conditional alleles for the temporal and spatial ablation of genes. The AMSR also provides services for the generation of transgenic mouse lines either by conventional random transgene integration, or by targeted insertion of transgenes into safe harbor genomic loci to ensure stable gene expression. An AAALAC-accredited AMSR animal facility provides specific pathogen-free (SPF) rodent housing and a broad spectrum of animal husbandry services, as well as the services of a board-certified veterinary pathologist. Comprehensive mouse reproductive services for embryo and sperm cryopreservation and re-derivation of transgenic and gene-targeted mouse lines as well as IVF services are offered. The AMSR established a Gene Modification Service to provide a complete service for the rapid and cost-efficient generation of genetically modified mouse lines to MECC investigators. Furthermore, the AMSR provides a robust array of xenograft methodologies for cell implantation and propagation of tumor grafts by serial transplantations, and supports pre- clinical studies on novel anticancer agents in murine tumors as well as in human patient-derived tumor xenografts (PDX). Finally, the AMSR provides in vivo IVIS imaging of animals bearing tumors that express bioluminescent or fluorescent proteins, allowing non-invasive quantitation of tumor growth in mice. The AMSR has three Specific Aims to accomplish these goals: 1) To provide comprehensive services required for the generation of genetically modified mouse models of human cancer and the generation of xenotransplantation mouse models for studying hematologic malignancies and patient-derived solid tumor xenografts; 2) To provide services for husbandry and preservation of genetically modified mouse lines including sperm and embryo freezing for cryopreservation, re- derivation of transgenic and gene-targeted mouse lines and in vitro fertilization (IVF) services; and 3) To provide innovative methods and technologies to support MECC research including novel CRISPR technologies such as base edit technology, CRISPR interference (CRISPRi), CRISPR activation (CRISPRa) and CRISPR RNA technology for knockdown of gene expression as well as novel imaging technologies to increase the range of detectable fluorescent labels in tumor cells. OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page

View original record on NIH RePORTER →